When was the dengue vaccine approved?
In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
Is there an approved dengue vaccine?
In May 2019, Dengvaxia was approved by the Food and Drug Administration (FDA) for use in children and adolescents aged 9–16 years (referred to in this report as children) living in an area where dengue is endemic and having had laboratory-confirmed previous DENV infection.
What is the name of the dengue vaccine?
Authorisation details
| Product details | |
|---|---|
| International non-proprietary name (INN) or common name | dengue tetravalent vaccine (live, attenuated) |
| Therapeutic area (MeSH) | Dengue |
| Anatomical therapeutic chemical (ATC) code | J07BX |
What is the first dengue vaccine?
Vaccines for Dengue Fever The first recommended dengue vaccine (CYD-TDV) is a live recombinant tetravalent vaccine evaluated in phase 3 trials as a three-dose series (0-, 6-, 12-month schedule).
How long does the dengue vaccine last?
How long will protection last? We are still learning about how long the vaccine protects children, but data from clinical trials indicate that the vaccine can protect children against dengue for at least 6 years.
Who is eligible for dengue vaccine?
A new dengue vaccine is approved for use in children aged 9–16 years with laboratory-confirmed previous dengue virus infection and living in areas where dengue is endemic (occurs frequently or continuously). Endemic areas include some U.S. territories and freely associated states.
How many years is Dengvaxia studied?
Dengvaxia® has been studied in 26 clinical trials including more than 41,000 volunteers. At least one injection of final tetravalent formulation has been administered to more than 28,500 individuals from 9 months through 60 years of age and 20,974 individuals aged 9 years through 45 years.
Who needs dengue vaccine?
Who can get the dengue vaccine? It is approved for use in children 9–16 years old who have a previous history of laboratory-confirmed dengue infection. Only children with laboratory-confirmed evidence of previous dengue infection should be vaccinated.
How is yellow fever vaccine given?
There’s a very effective vaccine that can stop you getting yellow fever if you’re travelling to an area where the infection is found. It’s given as an injection into your upper arm. But even if you have been vaccinated, it’s important to prevent insect bites as mosquitoes can also spread other serious illnesses.
Is Dengvaxia available in USA?
Sign up for Daily Recap “Today’s FDA approval of Dengvaxia allows us to bring a critical medical prevention tool to at-risk populations, helping combat and prevent dengue, particularly among children, in U.S. dengue-endemic areas,” Dr.
Is Dengvaxia tested?
Dengvaxia is available for use in children and adolescents 9–16 years old with laboratory-confirmed previous dengue virus infection and living in an area where dengue is endemic (occurs frequently or continuously)….Pre-vaccination screening testing standards.
| Test Characteristic | Minimum |
|---|---|
| Sensitivity | ≥75% |
| Specificity† | ≥98% |